ClinicalTrials.gg
RecruitingNCT07473375Updated Mar 16, 2026

Indicators Affecting PVT Recanalization

An observational study in Portal Vein Thrombosis, Cirrhosis and Portal Hypertension Related to Cirrhosis, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Primary conditionHypertension, PortalRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertension, Portal
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Hypertension, Portal.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Zhongshan Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2017; still recruiting 9 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,500
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hypertension, Portal by Shanghai Zhongshan Hospital — 5 open to participants now, 6 under way, none of them phase 3. Hypertension, Portal · Shanghai Zhongshan Hospital.

Planned enrollment
2nd of 10
1,500 · median 1,033
Started
2017
with 1 other
Observational
10 of 15
5 open now
Registered
14th of 15
by date

Among the 15 studies in Hypertension, Portal by Shanghai Zhongshan Hospital, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2017, is one of 10 observational ones, and was the 14th registered.

Hypertension, Portal

376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.

Browse Hypertension, Portal studies →

Open to participants now

5 of the 15 studies in Hypertension, Portal by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 68 Hypertension, Portal studies recruiting now, 33 (49%) set no upper age limit and 12 (18%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypertension, Portal by Shanghai Zhongshan Hospital, or all of them as a file.
02

Study summary

This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV). It aimed to provide insights into the diagnosis, follow-up, and factors influencing PVT recanalization, to help patients, families, and healthcare providers understand the disease and related clinical management.

03

Conditions studied

  • Portal Vein Thrombosis
  • Cirrhosis
  • Portal Hypertension Related to Cirrhosis
  • Portal Hypertension, Noncirrhotic

Browse trials for

04

In context

Hypertension, Portal Reclassified

376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 150 across 135 observational studies indexed under Hypertension, Portal.

Browse Hypertension, Portal studies →

Lead sponsor

Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.

Compared within Hypertension, Portal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

This study enrolled adult patients with cirrhosis and confirmed gastroesophageal varices who presented to Zhongshan Hospital, Fudan University, and were diagnosed with portal vein thrombosis (PVT)upon admission.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy;

    • all patients were diagnosed as PVT by CTA at admission.

Exclusion criteria

Exclusion Criteria:

  • patients with hepatocellular carcinoma;

    • patients with extrahepatic ;

      • history of liver transplantation or TIPS;

        • lack of information regarding anticoagulation therapy;

          • those with cavernous transformation of the portal vein(CTPV) .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,500 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. PVT recanalization at 1 year

    Time frame: From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 1 year, death, or the last follow-up, whichever came first

Secondary outcomes

  1. Occurrence of all-cause death (competing event)

    Time frame: From the date of admission confirmation of PVT to the occurrence of death, or the last follow-up, whichever came first

  2. PVT recanalization at 5 years

    Time frame: From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 5 year, death, or the last follow-up, whichever came first

  3. Occurrence of non-improved PVT

    defined as unchanged thrombus size, \<50% thrombus reduction, or thrombus extension to new venous segments

    Time frame: From the date of admission confirmation of PVT to the last radiological follow-up at 1 year, or death, whichever came first

08

Study locations

1 of 1 sites recruiting
  • Shanghai, Shanghai Municipality 200032, China
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Dec 2027, 131 months after the start.

Of 61 non-industry observational studies under Hypertension, Portal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 256. This study's planned 131 months is above that.

Counting every sponsor, half of 65 studies reached it within 42 months; a quarter within 30 and three quarters within 256.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 16, 2026
StartActual
Jan 1, 2017
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07473375
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Jan 1, 2017
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 16, 2026

Study contacts

Siyu Jiang, Dr.
Contact
ksjsy1996926@126.com
+86-15121068078

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion